Skip to main content

Better Bioprinting by Light-sheet Lithography

Objective

Bioprinting is considered the most promising method to produce functional engineered tissues with physiological properties. Successful tissue engineering will open research avenues for drug testing and therapeutic and will therefore raise much interest not only in the academia, but also pharma and clinical sectors. Current bioprinting methods are limited by combinations of insufficient speed, spatial resolution and cell viability. Since these technologies often suffer from poor spatial resolution and inability to control biomechanical properties, they fail to mimic the heterogeneous nature of native tissues. B-BRIGHTER aims to develop a novel bioprinting technology able to produce engineered tissues with high spatial resolution at high printing speed using an original top-down lithography approach. In contrast with current bottom up, layer-by-layer bioprinting methods, B-BRIGHTER aims at ultra high-speed digital light-sheet illumination strategy to selectively photo-crosslink cell-laden hydrogels mimicking specific tissues, in confined voxels and produce three-dimensional complex geometries. Previous advances from the BRIGHTER project will be extended by building complex bioengineered skin, cornea and gut tissue models, all of which represent pioneering examples for bioengineering, and its application for cell therapy, drug discovery and toxicology. Together with the work on patterning technology, bioink and application, a basis will be established for formulating a valid business case for a bioprinting product. The work on exploitation activities will ultimately result in a go-no go decision for the industrialisation of a bioprinting product and a commercial path forward. Ultimately, the goal of the B-BRIGHTER project is to provide a radically new bioprinting technology to boost the performance of various engineered tissues which in turn will promote improved healthcare opportunities, as well as business and employment advances in the European Union and beyond.

Coordinator

MYCRONIC AB
Net EU contribution
€ 381 875,00
Address
Nytorpsvagen 9
183 03 Taby
Sweden

See on map

Region
Östra Sverige Stockholm Stockholms län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00

Participants (4)

FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA
Spain
Net EU contribution
€ 382 206,00
Address
Carrer Baldiri Reixac Planta 2a 10-12
08028 Barcelona

See on map

Region
Este Cataluña Barcelona
Activity type
Research Organisations
Non-EU contribution
€ 0,25
JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN
Germany
Net EU contribution
€ 477 875,00
Address
Theodor W Adorno Platz 1
60323 Frankfurt Am Main

See on map

Region
Baden-Württemberg Stuttgart Stuttgart, Stadtkreis
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY
Israel
Net EU contribution
€ 435 943,00
Address
Senate Building Technion City
32000 Haifa

See on map

Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,75
CELLENDES GMBH
Germany
Net EU contribution
€ 415 432,00
Address
Markwiesenstr 55
72770 Reutlingen

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Baden-Württemberg Tübingen Reutlingen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,50